title: Off-Label Uses of Topical Calcineurin Inhibitors.
abstract: Topical calcineurin inhibitors (TCIs) have been proposed as an alternative, long-term treatment option to topical corticosteroids, without the side effects commonly associated with steroid use. Currently, TCIs are only approved for treatment of atopic dermatitis in patients 2 years of age or older. This article reviews the off-label uses of TCIs and their efficacy in the treatment of cutaneous diseases. Studies show that TCIs may be effective in treating/managing a variety of skin conditions. The strongest evidence based support on clinical outcomes has been reported for allergic contact dermatitis, lichen planus, psoriasis, seborrheic dermatitis and vitiligo.
authors.affiliation: Division of Dermatology & Cutaneous Sciences, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
authors.forename: E
authors.initials: E
authors.lastname: Wong
authors.affiliation: Division of Dermatology & Cutaneous Sciences, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
authors.forename: A
authors.initials: A
authors.lastname: Kurian
mesh_terms: D000287:Administration, Topical; D065095:Calcineurin Inhibitors / Q000008:administration & dosage*; D017449:Dermatitis, Allergic Contact / Q000188:drug therapy; D012628:Dermatitis, Seborrheic / Q000188:drug therapy; D006801:Humans; D008010:Lichen Planus / Q000188:drug therapy; D056687:Off-Label Use; D011565:Psoriasis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D014820:Vitiligo / Q000188:drug therapy
chemical_list: D065095:Calcineurin Inhibitors